Effect of Digoxin Use among Medicaid Enrollees with Atrial Fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 10, Issue 5, 2017, Pages

  Adedinsewo, Demilade ^a,b   Xu, Junjun ^a   Agasthi, Pradyumna ^a,b   Oderinde, Adesoji ^a,b   Adekeye, Oluwatoyosi ^a   Sachdeva, Rajesh ^a,b   Rust, George ^c   Onwuanyi, Anekwe ^a,b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

atrial fibrillation; digoxin; heart failure; hospitalization; Medicaid

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; WARFARIN; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; CHADS2 SCORE; ETHNICITY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAID; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADMINISTRATIVE CLAIMS (HEALTH CARE); ADOLESCENT; AFRICAN AMERICAN; CAUCASIAN; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DISEASE COURSE; DRUG UTILIZATION REVIEW; ETHNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; DIGOXIN; DISEASE PROGRESSION; DRUG UTILIZATION REVIEW; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MEDICAID; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85019545916     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.116.004573     Document Type: Article

References (45)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046. doi: 10.1161/01. CIR.0000140263.20897.42.
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539. doi: 10.1016/j.amjcard.2009.07.022.
4. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313-320. doi: 10.1161/CIRCOUTCOMES.110.958165.
5. Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol. 2004;43:429-435. doi: 10.1016/j.jacc.2003.09.035.
6. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris TB, Pencina MJ, D'Agostino RB Sr, Levy D, Kannel WB, Wang TJ, Kronmal RA, Wolf PA, Burke GL, Launer LJ, Vasan RS, Psaty BM, Benjamin EJ, Gudnason V, Heckbert SR. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170:1909-1917. doi: 10.1001/archinternmed.2010.434.
7. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-117. doi: 10.1016/j.ahj.2009.05.010.
8. Golwala H, Jackson LR 2nd, Simon DN, Piccini JP, Gersh B, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Fonarow GC, Peterson ED, Thomas KL. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from outcomes registry for better informed treatment for atrial fibrillation registry. Am Heart J. 2016;174:29-36.
9. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015;115:901-906. doi: 10.1016/j.amjcard.2015.01.013.
10. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013;6:525-533. doi: 10.1161/CIRCOUTCOMES.111.000079.
11. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015;8:49-58. doi: 10.1161/CIRCEP.114.002292.
12. Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breithardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowitz SD, Nessel CC, Fox KA, Califf RM, Piccini JP, Patel MR; ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015;385:2363-2370. doi: 10.1016/S0140-6736(14)61836-5.
13. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015;36:1831-1838. doi: 10.1093/eurheartj/ehv143.
14. Reynolds MR. Outcomes with digoxin in atrial fibrillation: more data, no answers. J Am Coll Cardiol. 2014;64:669-671. doi: 10.1016/j.jacc.2014.04.070.
15. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2691-2698.
16. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
17. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt S, Holmes TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich PA. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64:660-668. doi: 10.1016/j.jacc.2014.03.060.
18. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J. 2013;34:1481-1488. doi: 10.1093/eurheartj/ehs348.
19. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007;28:2346-2353. doi: 10.1093/eurheartj/ehm308.
20. Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38:874-880. doi: 10.1161/01. STR.0000258004.64840.0b.
21. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: Results from the outcomes registry for better informed treatment of atrial fibrillation (orbit-af). Am Heart J. 2014;167:735-742 e732.
22. Gbadebo TD, Okafor H, Darbar D. Differential impact of race and risk factors on incidence of atrial fibrillation. Am Heart J. 2011;162:31-37. doi: 10.1016/j.ahj.2011.03.030.
23. Taylor AL. The African American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44-48. doi: 10.1016/j.amjcard.2005.07.033.
24. Cheng JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther. 2006;28:666-678. doi: 10.1016/j.clinthera.2006.05.007.
25. Taylor AL, Sabolinski ML, Tam SW, Ziesche S, Ghali JK, Archambault WT, Worcel M, Cohn JN; A-HeFT Investigators. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African- American heart failure trial. J Card Fail. 2012;18:600-606. doi: 10.1016/j.cardfail.2012.06.526.
26. Saunders E. Hypertension in minorities: blacks. Am J Hypertens. 1995;8(12 pt 2):115s-119s.
27. Heart Failure Society of America. Management of heart failure in special populations. J Card Fail. 2006;12:e115-119.
28. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin- converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357. doi: 10.1056/NEJM200105033441802.
29. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Hfsa 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-194.
30. McAlpine DD, Beebe TJ, Davern M, Call KT. Agreement between selfreported and administrative race and ethnicity data among Medicaid enrollees in Minnesota. Health Serv Res. 2007;42(6 pt 2):2373-2388. doi: 10.1111/j.1475-6773.2007.00771.x.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
32. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57-64. doi: 10.1016/j.ahj.2008.03.010.
33. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(6 suppl):S114-S120. doi: 10.1097/MLR.0b013e3181dbebe3.
34. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156. doi: 10.1093/aje/kwj149.
35. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158:280-287.
36. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-522. doi: 10.1097/EDE.0b013e3181a663cc.
37. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
38. Chen Y, Cai X, Huang W, Wu Y, Huang Y, Hu Y. Increased all-cause mortality associated with digoxin therapy in patients with atrial fibrillation: an updated meta-analysis. Medicine (Baltimore). 2015;94:e2409. doi: 10.1097/MD.0000000000002409.
39. Mathew J, Wittes J, McSherry F, Williford W, Garg R, Probstfield J, Yusuf S; Digitalis Investigation Group. Racial differences in outcome and treatment effect in congestive heart failure. Am Heart J. 2005;150:968-976. doi: 10.1016/j.ahj.2005.03.060.
40. Turagam MK, Velagapudi P, Visotcky A, Szabo A, Kocheril AG. African Americans have the highest risk of in-hospital mortality with atrial fibrillation related hospitalizations among all racial/ethnic groups: a nationwide analysis. Int J Cardiol. 2012;158:165-166. doi: 10.1016/j. ijcard.2012.04.090.
41. Naderi S, Rodriguez F, Wang Y, Foody JM. Racial disparities in hospitalizations, procedural treatments and mortality of patients hospitalized with atrial fibrillation. Ethn Dis. 2014;24:144-149.
42. Tomfohr LM, Pung MA, Dimsdale JE. Mediators of the relationship between race and allostatic load in African and White Americans. Health Psychol. 2016;35:322-332. doi: 10.1037/hea0000251.
43. Geronimus AT, Hicken M, Keene D, Bound J. "Weathering" and age patterns of allostatic load scores among blacks and whites in the United States. Am J Public Health. 2006;96:826-833. doi: 10.2105/AJPH.2004.060749.
44. Cooper R, Cutler J, Desvigne-Nickens P, Fortmann SP, Friedman L, Havlik R, Hogelin G, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the united states: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
45. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178-186. doi: 10.1093/eurheartj/ehi687.